In the last trading session, 1.09 million shares of the Nuvation Bio Inc (NYSE:NUVB) were traded, and its beta was 1.36. Most recently the company’s share price was $2.21, and it changed around -$0.09 or -3.91% from the last close, which brings the market valuation of the company to $739.86M. NUVB currently trades at a discount to its 52-week high of $4.16, offering almost -88.24% off that amount. The share price’s 52-week low was $0.95, which indicates that the current value has risen by an impressive 57.01% since then. We note from Nuvation Bio Inc’s average daily trading volume that its 10-day average is 1.18 million shares, with the 3-month average coming to 1.50 million.
Nuvation Bio Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended NUVB as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Nuvation Bio Inc is expected to report earnings per share of -0.13 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Nuvation Bio Inc (NYSE:NUVB) trade information
Instantly NUVB has showed a red trend with a performance of -3.91% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.51 on recent trading dayincreased the stock’s daily price by 11.95%. The company’s shares are currently up 46.36% year-to-date, but still down -11.24% over the last five days. On the other hand, Nuvation Bio Inc (NYSE:NUVB) is -10.53% down in the 30-day period. We can see from the shorts that 9.97 million shares have been sold at a short interest cover period of 5.79 day(s).
The consensus price target as assigned by Wall Street analysts is $6, which translates to bulls needing to increase their stock price by 63.17% from its current value. Analyst projections state that NUVB is forecast to be at a low of $5 and a high of $10.
Nuvation Bio Inc (NUVB) estimates and forecasts
Nuvation Bio Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -17.54 percent over the past six months and at a -502.86% annual growth rate that is well below the industry average of 17.50%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -44.40% in revenue this quarter, and will report a decrease of -116.70% in the next quarter.
NUVB Dividends
Nuvation Bio Inc’s next quarterly earnings report is expected to be released in November.
Nuvation Bio Inc (NYSE:NUVB)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 27.01% of Nuvation Bio Inc shares, and 43.99% of them are in the hands of institutional investors. The stock currently has a share float of 60.27%. Nuvation Bio Inc stock is held by 194.0 institutions, with FMR LLC being the largest institutional investor. By 2024-06-30, it held 13.1578% of the shares, which is about 28.82 million shares worth $84.16 million.
ECOR1 CAPITAL, LLC, with 8.7696% or 19.21 million shares worth $56.09 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
